New Weight-Loss Drugs Show Promise Amid Mild Side Effects
New data from Novo Nordisk and Eli Lilly indicate their weight-loss drugs show promising results with mild side effects. Novo Nordisk's CagriSema reported significant weight loss and positive outcomes on blood sugar levels. Eli Lilly's orforglipron is expected to deliver key results by the third quarter.
Recent studies have revealed promising results for Novo Nordisk's experimental weight-loss drug, CagriSema, with most side effects being mild to moderate. Despite positive outcomes in weight reduction and blood sugar levels, investor confidence took a hit, leading to a dip in company shares.
Meanwhile, Eli Lilly reported that its obesity treatment pill, orforglipron, aided diabetics in losing weight and managing blood sugar. The company anticipates sharing critical findings for its use in overweight and obese non-diabetics during the third quarter.
Eli Lilly plans to submit Phase 3 findings to global regulatory bodies by year-end, while the FDA typically reviews new drug applications within 10 months of submission, potentially paving the way for these innovative treatments to reach the public soon.
(With inputs from agencies.)
ALSO READ
Novo Nordisk's Amycretin: Pioneering Weight Loss Revolution
Novo Nordisk's Weight-loss Drug Trial and Eli Lilly's Promising Obesity Treatment
USDA's Bird Flu Vaccine Plan and Lilly’s Obesity Drug Trials
Novo Nordisk Ends Collaboration with Hims & Hers Over Wegovy Distribution
Novo Nordisk Ends Partnership with Hims & Hers Over Wegovy Sales
Google News